A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Eleftherios Mylonakis, MD and Panayiotis D. Ziakas, MD, MSc, PhD
Allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh antimicrobial stewardship interventions’ risks and benefits.
AMA J Ethics. 2021;23(8):E631-638. doi:
10.1001/amajethics.2021.631.
Underlying ideological foundations of stigma and equipment inadequacy include thin-centrism and inadequate representation of fat people in health care organizational leadership.
AMA J Ethics. 2023;25(7):E528-534. doi:
10.1001/amajethics.2023.528.
Decisions about where and to whose professional stewardship patients are admitted are influenced by federal policies of which physicians might not be aware.
AMA J Ethics. 2023;25(12):E901-908. doi:
10.1001/amajethics.2023.901.
Amy B. Cadwallader, PhD, Kavitha Nallathambi, MPH, MBA, and Carly Ching, PhD
Poor-quality antimicrobial medicines continue to proliferate across supply chains, threatening patients’ health and safety, especially in low- and middle-income regions.
AMA J Ethics. 2024;26(6):E472-478. doi:
10.1001/amajethics.2024.472.